Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 80.4% in July

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totaling 145,807 shares, an increase of 80.4% from the June 30th total of 80,824 shares. Approximately 0.9% of the company’s stock are sold short. Based on an average trading volume of 139,949 shares, the days-to-cover ratio is currently 1.0 days.

Institutional Trading of Allarity Therapeutics

Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in Allarity Therapeutics by 274.1% during the fourth quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after buying an additional 181,426 shares in the last quarter. Private Advisor Group LLC bought a new position in shares of Allarity Therapeutics during the 3rd quarter worth about $441,000. Citadel Advisors LLC bought a new position in shares of Allarity Therapeutics during the 3rd quarter worth about $149,000. DRW Securities LLC acquired a new stake in shares of Allarity Therapeutics during the 4th quarter valued at about $133,000. Finally, XTX Topco Ltd bought a new stake in Allarity Therapeutics in the second quarter valued at about $51,000. Institutional investors own 11.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Ascendiant Capital Markets upped their price objective on shares of Allarity Therapeutics from $9.75 to $10.25 and gave the stock a “buy” rating in a report on Monday, June 8th. Wall Street Zen raised Allarity Therapeutics to a “hold” rating in a report on Saturday, May 30th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $10.25.

Allarity Therapeutics Price Performance

Shares of Allarity Therapeutics stock opened at $1.16 on Thursday. The company has a market cap of $18.46 million, a PE ratio of -1.61 and a beta of 0.53. The firm has a fifty day moving average price of $1.39 and a two-hundred day moving average price of $1.25. Allarity Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.35.

Allarity Therapeutics (NASDAQ:ALLR) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.05. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. Analysts expect that Allarity Therapeutics will post -0.92 earnings per share for the current fiscal year.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical?stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small?molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid?stage clinical trials.